or Try an Advanced Search...

    Technical Analysis for HUGE - FSD Pharma Inc. - Class B Subordinate Voting Shares

    Grade Last Price % Change Price Change
    F 0.35 -4.31% -0.02
    HUGE closed down 4.31 percent on Wednesday, May 8, 2024, on 1.46 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 10
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical HUGE trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -4.31%
    NR7 Range Contraction -4.31%
    Narrow Range Bar Range Contraction -4.31%
    Inside Day Range Contraction -4.31%
    Wide Bands Range Expansion -4.31%
    Oversold Stochastic Weakness -4.31%
    Older End-of-Day Signals for HUGE ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 11 hours ago
    New 52 Week Low about 12 hours ago
    60 Minute Opening Range Breakdown about 12 hours ago
    Down 3% about 14 hours ago
    2x Volume Pace about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    HUGE Chart by TradingView
    Basic chart:

    Profile

    FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Cobourg, Canada.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Health Sciences Autoimmune Disease Cannabis Chronic Pain Central Nervous System Disorders Nervous System Disorders Medical Cannabis Bioenergy Cannabis In Canada Cannabinoid Skeletal System Antiemetics Musculoskeletal System Antioxidants

    Is HUGE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
    Apr 22 FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
    Apr 17 FSD Pharma expands pipeline investigation to include weight loss and liver health products
    Apr 17 FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
    Apr 15 FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
    Apr 8 FSD Pharma receives Nasdaq notification regarding minimum bid price deficiency
    Apr 8 FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
    Apr 2 FSD Pharma GAAP EPS of -$0.46
    Mar 30 Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
    Mar 27 FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
    See more HUGE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.6799
    52 Week Low 0.34
    Average Volume 268,776
    200-Day Moving Average 0.98
    50-Day Moving Average 0.62
    20-Day Moving Average 0.45
    10-Day Moving Average 0.40
    Average True Range 0.05
    RSI (14) 18.03
    ADX 46.04
    +DI 9.72
    -DI 30.21
    Chandelier Exit (Long, 3 ATRs) 0.49
    Chandelier Exit (Short, 3 ATRs) 0.49
    Upper Bollinger Bands 0.60
    Lower Bollinger Band 0.31
    Percent B (%b) 0.14
    BandWidth 64.23
    MACD Line -0.08
    MACD Signal Line -0.08
    MACD Histogram -0.0013
    Fundamentals Value
    Market Cap 13.71 Million
    Num Shares 39.4 Million
    EPS -0.58
    Price-to-Earnings (P/E) Ratio -0.60
    Price-to-Sales 91.86
    Price-to-Book 2.28
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.40
    Resistance 3 (R3) 0.40 0.39 0.39
    Resistance 2 (R2) 0.39 0.38 0.39 0.39
    Resistance 1 (R1) 0.37 0.37 0.36 0.37 0.39
    Pivot Point 0.35 0.35 0.35 0.35 0.35
    Support 1 (S1) 0.33 0.34 0.33 0.33 0.31
    Support 2 (S2) 0.32 0.33 0.32 0.31
    Support 3 (S3) 0.30 0.32 0.30
    Support 4 (S4) 0.30